(1) Bioresource Overview
The PCRC was established in 2004 to bring together researchers from different academic institutions and hospitals in understanding the molecular and cellular basis of prostate cancer development and progression. The PCRC includes four clinical sites; Mater Misericordiae University Hospital, St James’s Hospital, Beaumont Hospital and the Adelaide & Meath incorporating the National Children’s Hospital and four research institutions; Conway Institute of Biomolecular and Biomedical Research, University College Dublin; Institute of Molecular Medicine, Trinity College Dublin; Royal College of Surgeons in Ireland Education and Research Centre and National Centre for Sensor Research, Dublin City University.
One of the objectives of the PCRC was to establish a bioresource. The first samples to be incorporated into the bioresource were collected in 2002. The PCRC established collection and temporal storage sites at its hospitals, following ethical approval by each of the hospital’s ethics committees. The PCRC uses an agreed collection model, with agreed standard operating procedures (informed consent, sample collection, processing and transportation) that are implemented across the different sites, ensuring uniformity of the bioresource. Samples are temporarily stored at the collection centres using monitored storage facilities and periodically collected and transferred to the PCRC bioresource. They are then processed for long term storage. There is a bioresource management system that facilitates effective storage, retrieval, tracking and dissemination of biological samples.
The bioresource has a Bioresource Information and Management System (BIMS) which is a central data repository for the sample, clinical and research data. The BIMS data originates from the hospital and research sites. Research nurses upload de-identified clinical, sample and pathology data and PCRC researchers upload research data from biological assessment. Uploading is done over a secure web browser to ensure confidentiality and security. BIMS allows researchers to identify what samples are available and where they are located and associated clinical and biological assessment data.
Biological samples and associated clinical data.
Prostate cancer, bioresource, biological samples.
All counties of Southern Ireland.
Start date 2002 to present; with collection, processing and storage of samples indefinite.
Temporal coverage for accessibility
- Patients deemed suitable for recruitment are identified by research nurses.
- Potential patients are contacted and informed consent sought.
- After obtaining informed consent, research nurses organise with the patient to collect blood and urine samples prior to surgery. Tissues are collected at time of TURPs or radical prostatectomy.
- Blood and urine samples are processed by the research nurses and temporarily stored at hospital sites. The tissues as processed by pathology laboratory staff and stored. All samples are processed using the agreed SOPs.
- Clinical, pathological and sample data are recorded electronically into BIMS by research nurses.
- Serum, plasma, urine and fresh frozen tissue (clarified in next section – Stabilization/preservation) are periodically collected from collection sites and transferred to the combined bioresource. FFPE blocks are stored at the pathology laboratories until required for biological assessment.
Standard Operating Procedures used include consent, sample collection, storage, retrieval, tracking and data management.
Bloods: vacutainer, EDTA, heparin.
Tissue: tissue container, 10% formalin; tissues for FFPE are kept in formalin until processing (processed within 2 hours of collection), fresh frozen tissues are transferred to freezing container and frozen in a 80°C freezer.
Type of long-term preservation
Bloods: plasma, serum, whole blood.
Tissue: fresh frozen, FFPE.
Plasma, serum and fresh frozen tissue: 80°C.
FFPE tissues: room temperature.
DNA and RNA whole blood: 20°C.
Shipping temperature from patient/source to preservation
Bloods and tissue: room temperature.
Shipping temperature from storage to research use
Plasma, serum, fresh frozen tissue, and DNA/RNA whole blood: 80°C (on dry ice).
FFPE tissues: room temperature as FFPE blocks.
Quality assurance measures
- All the samples are collected, processed and transported by following agreed SOPs across the different sites.
- All personnel handling samples are trained.
- Any modifications or revisions of SOPs are documented.
- All records pertaining to samples, equipment and consumables are safely maintained.
- Tissues are verified by pathologists.
- Sample processing methods are validated via literature reviews, end user feed-back and/or laboratory quality control results.
- Periodic internal audits.
Source of associated data
Health records and questionnaires.
Informed consent: The informed consent is structured along the following headings;
- What is the purpose of this research study?
- Why have I been chosen?
- Who is organizing this study?
- What will happen to me if I take part?
- Are there any disadvantages in taking part in this study?
- Are there any possible risks of taking part?
- What are the possible benefits of taking part?
- What happens after the study?
- Confidentiality- who will know I am taking part in this study?
- Hospital Research Ethics Committee Approval.
- What will happen to the results of the study?
- Voluntary participation.
- Further Research.
- Contact details.
Mater Misericordiae University Hospital, St James’s Hospital, Beaumont Hospital and the Adelaide & Meath hospital ethics committees.
There are ethical/legal limitations for the collection. The sample release and distribution does not breach Irish data protection legislation. The distribution of associated clinical data falls under the remit of the National Cancer Registry of Ireland (NCR). The NCR collects and distributes data on cancer patients in Ireland and is permitted to do so by specific data protection legislation. PCRC has partnered with the NCR. This allows the PCRC to focus on the biobanking and release of samples, and the NCR to focus on the dissemination of coded (de-identified) patient data, which thereby protects the privacy of individuals.
Loss of patients leading to lack of follow up information and samples.
Lack of long-term funding.
(3) Bioresource description
Plasma, serum, urine, DNA, RNA, fresh frozen tissue, FFPE blocks and tissue slides.
Prostate Cancer Research Consortium Bioresource (Ireland).
PCRC Bioresource (Ireland).
The UCD Conway Institute of Biomolecular and Biomedical Research University College Dublin, Belfield, Dublin 4, Ireland. The bioresource is part of the UCD Conway Institute of Biomolecular and Biomedical Research. Some samples are stored at the Institute of Molecular Medicine St. James’s Hospital, James’s Street, Dublin 8, Ireland. This is a duplicate of the bioresource.
Prof. William Watson: email@example.com.
Type of sampling
Disease status of patients/source
Prostate cancer patients undergoing transurethral resection of the prostate or radical prostatectomy
Clinical characteristics of patients/source
Ethnical origin, family history, current symptoms, past medical/surgical history, current medical history, current medication, Gleason Grade, Gleason Score, Transrectal % core involvement, Digital Rectal Examination, age at time of surgery, cTNM staging, pTNM staging, capsular invasion, pre/post-Op PSA Prostate cancer patients
Size of the bioresource
Recruitment of patients and collection of biospecimens is ongoing and indefinite.
Vital state of patients/source
Clinical diagnosis of patients/source
TURPs; benign disease.
Radical prostatectomy; indolent, significant and aggressive, Gleason Score 4–10.
Tissue, serum, plasma and whole blood for DNA/RNA (Table 1).
|Number of aliquots (initial)||Volume/size|
|Fresh frozen tissue||1||N/A|
Complete access policy is in development and will be available on the resource website. Provisionally, access can be done case by case by contacting +353 (01) 716 6733 or a written demand can be sent to this address School of Medicine, Conway Institute, Belfield Dublin 4 Ireland.
(4) Reuse potential
Biological samples and associated clinical data from the PCRC Bioresource can be reused for biomarker discovery and validation research that would improve detection, prognosis and treatment of prostate cancer. This would include (i) using the samples and applying genomic, transcriptomic and proteomic technologies to identify novel biomarkers for early detection and improved prognosis of prostate cancer cases; (ii) using the samples to validate their biomarkers and correlate these molecular characteristics with disease progression phenotypes; and (iii) using the samples to evaluate their novel therapies in pre-clinical and potentially Phase I and Phase II studies.